We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH) (NASH)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Govind Ballabh Pant Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00681733
First Posted: May 21, 2008
Last Update Posted: May 21, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Govind Ballabh Pant Hospital
  Purpose
  1. To assess the metabolic factors in lean and obese patients with NASH.
  2. To compare the efficacy of pentoxifylline versus pioglitazone on the metabolic profile and liver histology of NASH patients.

Condition Intervention
Metabolic Parameters and Liver Histology Drug: Pioglitazone Drug: Pentoxifylline

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study Of Metabolic Factors And Efficacy Of Pentoxifylline Versus Pioglitazone In Lean And Obese Nash (Non-Alcoholic Steatohepatitis) Patients.

Resource links provided by NLM:


Further study details as provided by Govind Ballabh Pant Hospital:

Primary Outcome Measures:
  • Improvement in metabolic profile and histology [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Side effects [ Time Frame: 6 months ]

Estimated Enrollment: 20
Study Start Date: January 2007
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Pioglitazone
Drug: Pioglitazone
Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
Other Names:
  • Pentoxifylline - Trental
  • Pioglitazone - Piosys, Pioglar
Drug: Pioglitazone
30 mg OD
Other Name: Pioglar
Active Comparator: B
Pentoxifylline
Drug: Pentoxifylline
1200 mg/d
Other Name: Trental

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with biopsy proven NASH will be enrolled. Abdominal USG showing diffusely echogenic liver suggestive of fatty infiltration of liver.
  • ALT > 1.2 times the upper limit of normal for > 6 months.(atleast three readings one month apart)
  • Liver Biopsy showing steatosis affecting >10% of hepatocytes with necroinflammatory activity, ballooning hepatocytes &/ or fibrosis.

Exclusion Criteria:

  • Alcohol intake of more than 20g/wk
  • Evidence of viral/ autoimmune hepatitis
  • PBC (Primary biliary cirrhosis)
  • Biliary obstrution
  • Wilson disease
  • Haemchromatosis
  • Decompensated cirrhosis
  • Drug ingestion of the follwing drugs for a period of more than 4 weeks during past 6 weeks - Amiodarone, Methotrexate, Perhexiline, Glucocorticoids, Estrogens, Tamoxifen, Nifedipine, Diltiazem, Tamoxifen.
  • DM Type I
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00681733


Contacts
Contact: Barjesh Ch Sharma, MD, DM 91-011-2323-4242 ext 5203 drbcsharma@hotmail.com

Locations
India
Dr. Barjesh Chander Sharma Recruiting
New Delhi, India, 110001
Contact: Barjesh Ch Sharma, MD, DM    91-011-2323-4242 ext 5203    drbcsharma@hotmail.com   
Principal Investigator: Barjesh Ch Sharma, MD, DM         
Sponsors and Collaborators
Govind Ballabh Pant Hospital
Investigators
Principal Investigator: Barjesh Ch Sharma, MD, DM G B Pant Hospital Hospital, New Delhi
  More Information

Responsible Party: Dr. B C Sharma, professor, G B Pant Hospital, New Delhi, G B Pant Hospital, New Delhi
ClinicalTrials.gov Identifier: NCT00681733     History of Changes
Other Study ID Numbers: drakchaudhary
First Submitted: May 19, 2008
First Posted: May 21, 2008
Last Update Posted: May 21, 2008
Last Verified: May 2008

Keywords provided by Govind Ballabh Pant Hospital:
NASH Pentoxifylline Pioglitazone

Additional relevant MeSH terms:
Pioglitazone
Pentoxifylline
Hypoglycemic Agents
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Radiation-Protective Agents
Protective Agents
Vasodilator Agents
Free Radical Scavengers
Antioxidants